# Antiviral Therapy in Hepatitis B Virus (HBV)-Related Advanced Liver Disease Patients

> **NCT00823550** · PHASE4 · UNKNOWN · sponsor: **Yonsei University** · enrollment: 462 (estimated)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** Entecavir
- **DRUG:** Lamivudine

## Key facts

- **NCT ID:** NCT00823550
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-01
- **Primary completion:** 2014-07
- **Final completion:** 2015-07
- **Target enrollment:** 462 (ESTIMATED)
- **Last updated:** 2010-12-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00823550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00823550, "Antiviral Therapy in Hepatitis B Virus (HBV)-Related Advanced Liver Disease Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00823550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*